Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.

Nilsson R, Eriksson SE, Sjögren HO, Tennvall J.

Acta Oncol. 2011 Jun;50(5):711-8. doi: 10.3109/0284186X.2010.547215. Epub 2011 Jan 10.

PMID:
21214493
2.

Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.

Cancer Biother Radiopharm. 2012 Mar;27(2):134-40. doi: 10.1089/cbr.2011.1080. Epub 2012 Jan 9.

PMID:
22229635
3.

Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.

Nilsson R, Mårtensson L, Eriksson SE, Sjögren HO, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1033-42. doi: 10.1002/cncr.24790.

4.

Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Ohlsson T, Nilsson R, Tennvall J.

Cancer Biother Radiopharm. 2012 Apr;27(3):175-82. doi: 10.1089/cbr.2011.1132. Epub 2012 Mar 14.

PMID:
22417248
5.
6.

Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.

Eriksson SE, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J.

Cancer Biother Radiopharm. 2014 Aug;29(6):238-46. doi: 10.1089/cbr.2014.1625. Epub 2014 Jun 27.

PMID:
24971673
7.

High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.

Mårtensson L, Nilsson R, Ohlsson T, Sjögren HO, Strand SE, Tennvall J.

Cancer. 2010 Feb 15;116(4 Suppl):1043-52. doi: 10.1002/cncr.24791.

8.

The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.

Örbom A, Eriksson SE, Elgström E, Ohlsson T, Nilsson R, Tennvall J, Strand SE.

J Nucl Med. 2013 Aug;54(8):1404-10. doi: 10.2967/jnumed.112.117028. Epub 2013 Jun 26.

9.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

10.

Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.

Garkavij M, Tennvall J, Strand SE, Sjögren HO, JianQing C, Nilsson R, Isaksson M.

J Nucl Med. 1997 Jun;38(6):895-901.

11.

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

Remsen LG, Trail PA, Hellström I, Hellström KE, Neuwelt EA.

Neurosurgery. 2000 Mar;46(3):704-9.

PMID:
10719867
12.

Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma.

Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM.

Int J Cancer. 1997 Jul 29;72(3):477-85.

13.

Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts.

Kinuya S, Yokoyama K, Tega H, Hiramatsu T, Konishi S, Watanabe N, Shuke N, Aburano T, Takayama T, Michigishi T, Tonami N.

J Cancer Res Clin Oncol. 1999 Nov;125(11):630-6.

PMID:
10541970
14.

Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.

Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G, et al.

Clin Cancer Res. 1995 Dec;1(12):1447-54.

15.

Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.

Mårtensson L, Wang Z, Nilsson R, Ohlsson T, Senter P, Sjögren HO, Strand SE, Tennvall J.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7104s-7108s.

16.

Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.

Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.

Cancer Res. 1995 Dec 1;55(23 Suppl):5881s-5887s.

17.

Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2591-610.

PMID:
9406714
18.

Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.

Behr TM, Béhé M, Löhr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W.

Eur J Nucl Med. 2000 Jul;27(7):753-65.

PMID:
10952487
19.

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk